Overview
Retatrutide (LY3437943) is a synthetic peptide analogue designed as a triple-hormone receptor agonist. Unlike single or dual agonists, Retatrutide exhibits high affinity for three distinct receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon (GCG) receptor.
Scientific investigation of Retatrutide focuses on its biochemical interactions with pancreatic beta-cells, hepatocytes, and adipocytes. Research aims to understand its impact on glucose metabolism, lipid oxidation, and energy homeostasis. All discussion herein is limited strictly to in-vitro and in-vivo animal research contexts and does not imply clinical, cosmetic, or therapeutic use.
Peptide Type: Triple Agonist (GIP / GLP-1 / Glucagon)
Biochemical Characteristics
Retatrutide is a chemically modified peptide backbone containing 39 amino acids. Its structure includes a C20 fatty diacid moiety attached via a linker, which promotes binding to plasma albumin. This biochemical modification is designed to extend the peptide's half-life and stability within experimental systems.
Biochemical analyses demonstrate that Retatrutide acts as a potent agonist across all three target receptors. By incorporating glucagon receptor activity alongside GIP and GLP-1, the molecule is studied for its unique ability to influence energy expenditure and mitochondrial function, distinct from earlier generations of mono- and dual-agonists.
Sequence: Modified peptide backbone (39 AA) with C20 fatty acid moiety
Molecular Formula: C₂₂₃H₃₄₃N₄₅O₆₉
Molecular Weight: ~4,731.33 g/mol
CAS Number: 2381089-83-2
PubChem CID: 163340104
Research Applications
Retatrutide is widely utilized in laboratory research to investigate metabolic signaling pathways involving insulin secretion, glucagon suppression, and hepatic lipid metabolism. Experimental systems include diet-induced obesity (DIO) rodent models, hepatocyte cultures for steatosis research, and glycemic control assays.
Additional applications include the investigation of lipolysis regulation, mitochondrial turnover in adipose tissue, and the comparative analysis of receptor internalization rates against established dual-agonists under controlled experimental conditions.
Pathway / Mechanistic Context
Mechanistic studies indicate that Retatrutide modulates multiple biochemical pathways simultaneously. By activating the GLP-1 and GIP receptors, it influences insulin signaling cascades and gastric motility markers. Uniquely, its activation of the Glucagon (GCG) receptor is theorized to enhance thermogenesis and energy expenditure.
Gene-expression analyses further demonstrate that Retatrutide can influence transcriptional networks associated with fatty acid oxidation in the liver and browning of white adipose tissue. The simultaneous engagement of these three receptors allows researchers to study the synergistic effects of metabolic hormone signaling in a way not possible with single-receptor ligands.
Preclinical Research Summary
Preclinical investigations of Retatrutide include extensive trials in murine models of obesity and non-alcoholic fatty liver disease (NAFLD). Studies have focused on endpoints such as body weight trajectory, hepatic fat fraction, and plasma lipid profiles.
Experimental observations report significant alterations in energy balance, enhanced lipid clearance from the liver, and modulation of glycemic indices in animal subjects. Comparative studies often benchmark these effects against mono-agonists to quantify the additive value of glucagon receptor engagement. These findings are presented solely as laboratory observations without implication of clinical or therapeutic outcomes.
Form & Analytical Testing
Retatrutide is supplied as a synthetic research-grade peptide. Product identity and purity are confirmed using analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS). Batch-specific documentation is provided where applicable to verify the absence of fillers and ensure peptide integrity.
